R. Barron

Arash Naeim, Deborah A Marshall, Tim Bancroft, 2014, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

Prevalence of antibiotic resistance in US hospitals.

G. Oster, D. Weber, W. Langeberg, 2014, Diagnostic microbiology and infectious disease.

Effectiveness of Repeated Treatment with Botulinum Toxin Type A Across Different Conditions

M. Gordon, R. Barron, 2006, Southern medical journal.

Utilization of osteoporosis medication after a fragility fracture among elderly Medicare beneficiaries

A. Grauer, Yi Peng, R. Barron, 2016, Archives of Osteoporosis.

Risk of febrile neutropenia in patients receiving emerging chemotherapy regimens

G. Lyman, D. Weycker, J. Edelsberg, 2014, Supportive Care in Cancer.

Dose Delays, Dose Reductions, and Relative Dose Intensity in Patients With Cancer Who Received Adjuvant or Neoadjuvant Chemotherapy in Community Oncology Practices.

G. Lyman, D. Patt, L. Asmar, 2015, Journal of the National Comprehensive Cancer Network : JNCCN.

Predictors of imminent non-vertebral fracture in elderly women with osteoporosis, low bone mass, or a history of fracture, based on data from the population-based Canadian Multicentre Osteoporosis Study (CaMos)

S. A. Jackson, W. Leslie, C. Kovacs, 2019, Archives of Osteoporosis.

Granulocyte-Colony Stimulating Factor Use and Medical Costs after Initial Adjuvant Chemotherapy in Older Patients with Early-Stage Breast Cancer

A. O'Hagan, G. Lyman, J. Legg, 2012, PharmacoEconomics.

Risk of infection among patients with non-metastatic solid tumors or non-Hodgkin’s lymphoma receiving myelosuppressive chemotherapy and antimicrobial prophylaxis in US clinical practice

G. Lyman, D. Weycker, J. Edelsberg, 2013, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.

Risk of mortality in patients with cancer who experience febrile neutropenia

G. Lyman, K. Tomic, S. Michels, 2010, Cancer.

Estimating the long-term functional burden of osteoporosis-related fractures

A. Mulcahy, Kandice A Kapinos, S. Fischer, 2017, Osteoporosis International.

Cost-effectiveness of pegfilgrastim versus 6-day filgrastim primary prophylaxis in patients with non-Hodgkin's lymphoma receiving CHOP-21 in United States

G. Lyman, R. Dubois, R. Barron, 2009, Current medical research and opinion.

Comparative Effectiveness of Filgrastim, Pegfilgrastim, and Sargramostim as Prophylaxis Against Hospitalization for Neutropenic Complications in Patients With Cancer Receiving Chemotherapy

G. Oster, J. Malin, D. Weycker, 2012, American journal of clinical oncology.

Risk and Consequences of Chemotherapy-Induced Febrile Neutropenia in Patients With Metastatic Solid Tumors.

G. Lyman, D. Weycker, J. Edelsberg, 2015, Journal of oncology practice.

Granulocyte colony-stimulating factor (G-CSF) patterns of use in cancer patients receiving myelosuppressive chemotherapy

C. Solid, T. Arneson, A. Blaes, 2014, Supportive Care in Cancer.

Cost-Effectiveness Analysis of Prophylaxis Treatment Strategies to Reduce the Incidence of Febrile Neutropenia in Patients with Early-Stage Breast Cancer or Non-Hodgkin Lymphoma

M. Weinstein, G. Lyman, M. Maschio, 2016, PharmacoEconomics.

Primary vs secondary prophylaxis with pegfilgrastim for the reduction of febrile neutropenia risk in patients receiving chemotherapy for non-Hodgkin’s lymphoma: cost-effectiveness analyses

M. Weinstein, G. Lyman, M. Skornicki, 2014, Journal of medical economics.

Comparative effectiveness of pegfilgrastim, filgrastim, and sargramostim prophylaxis for neutropenia-related hospitalization: two US retrospective claims analyses

A. Naeim, H. Henk, H. Tan, 2013, Journal of medical economics.

Cost-effectiveness of pegfilgrastim versus 6-day filgrastim primary prophylaxis in patients with non-Hodgkin's lymphoma receiving CHOP-21 in United States

G. Lyman, R. Dubois, R. Barron, 2009 .

Predictors of imminent risk of fracture in Medicare-enrolled men and women

Yan Hu, R. Barron, D. Chandler, 2020, Archives of Osteoporosis.

Repeated treatments with botulinum toxin type a produce sustained decreases in the limitations associated with focal upper-limb poststroke spasticity for caregivers and patients.

E. Elovic, A. Brashear, C. Turkel, 2008, Archives of physical medicine and rehabilitation.

Predictors of near-term fracture in osteoporotic women aged ≥65 years, based on data from the study of osteoporotic fractures

G. Oster, A. Grauer, J. Edelsberg, 2017, Osteoporosis International.

Determinants of imminent fracture risk in postmenopausal women with osteoporosis

G. Oster, A. Grauer, D. Weycker, 2020, Osteoporosis International.

Comparative effectiveness of granulocyte colony-stimulating factors to prevent febrile neutropenia and related complications in cancer patients in clinical practice: A systematic review

M. Samuel, R. Barron, Xiaoyan Li, 2016, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.

Comparative effectiveness of colony-stimulating factors in febrile neutropenia prophylaxis: how results are affected by research design.

H. Henk, L. Becker, R. Deeter, 2015, Journal of comparative effectiveness research.

Predicting imminent risk for fracture in patients aged 50 or older with osteoporosis using US claims data

M. Bonafede, N. Shi, R. Barron, 2016, Archives of Osteoporosis.

Patients' Perceptions of Physician-Patient Discussions and Adverse Events with Cancer Therapy

K. Zapert, D. Hershman, R. Barron, 2008, Archives of drug information.

Medication persistence and risk of fracture among female Medicare beneficiaries diagnosed with osteoporosis

R. Barron, L. Pinto, J. Liu, 2018, Osteoporosis International.

A Model for Assessing the Clinical and Economic Benefits of Bone-forming Agents for Reducing Fractures in Postmenopausal Women at High, Near-term Risk of Osteoporotic Fracture.

Claire E. O’Hanlon, John P. Caloyeras, B. Stollenwerk, 2017, Clinical therapeutics.

Two-year persistence and compliance with osteoporosis therapies among postmenopausal women in a commercially insured population in the United States

P. Juneau, L. Lopez-Gonzalez, R. Barron, 2017, Archives of Osteoporosis.

Risk and Healthcare Costs of Chemotherapy-Induced Neutropenic Complications in Women with Metastatic Breast Cancer

G. Lyman, D. Weycker, J. Edelsberg, 2012, Chemotherapy.

Costs Associated with Febrile Neutropenia in the US

G. Lyman, K. Tomic, S. Michels, 2012, PharmacoEconomics.

Comparison of hospitalization risk and associated costs among patients receiving sargramostim, filgrastim, and pegfilgrastim for chemotherapy‐induced neutropenia

D. Weycker, R. Barron, 2010, Cancer.

Testing a theoretical model of imminent fracture risk in elderly women: an observational cohort analysis of the Canadian Multicentre Osteoporosis Study

W. Leslie, C. Kovacs, G. Ioannidis, 2020, Osteoporosis International.

Evaluating use patterns of and adherence to medications for benign prostatic hyperplasia.

Tara K. Knight, D. Penson, M. Nichol, 2009, The Journal of urology.

Predictors of Imminent Risk of Nonvertebral Fracture in Older, High‐Risk Women: The Framingham Osteoporosis Study

D. Kiel, T. Travison, M. Hannan, 2019, JBMR plus.

Treatment patterns in patients with osteoporosis at high risk of fracture in Japan: retrospective chart review

S. Fujiwara, S. Baidya, A. Miyauchi, 2018, Archives of Osteoporosis.

Risk of chemotherapy-induced febrile neutropenia with early discontinuation of pegfilgrastim prophylaxis in US clinical practice

D. Weycker, A. Kartashov, R. Barron, 2015, Supportive Care in Cancer.

Comparative effectiveness of colony-stimulating factors for febrile neutropenia: a retrospective study

K. Tomic, J. Malin, D. Hurley, 2011, Current medical research and opinion.

A retrospective study of patients’ out-of-pocket costs for granulocyte colony-stimulating factors

K. Tomic, S. Long, Tzy-Chyi Yu, 2013, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.

Cancer chemotherapy treatment patterns and febrile neutropenia in the US Veterans Health Administration.

O. Baser, D. Dale, W. Langeberg, 2014, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

Risk and consequences of chemotherapy-induced neutropenic complications in patients receiving daily filgrastim: the importance of duration of prophylaxis

A. Glass, J. Legg, D. Weycker, 2014, BMC Health Services Research.

Reliability and validity of the Incontinence Quality of Life questionnaire in patients with neurogenic urinary incontinence.

B. Schurch, P. Reese, P. Denys, 2007, Archives of physical medicine and rehabilitation.

Systematic review of efficacy of dose-dense versus non-dose-dense chemotherapy in breast cancer, non-Hodgkin lymphoma, and non-small cell lung cancer.

G. Lyman, J. Natoli, R. Barron, 2012, Critical reviews in oncology/hematology.

Characterization and Prediction of Emergency Department Use in Chronic Daily Headache Patients

C. Kozma, F. Freitag, J. Osterhaus, 2005, Headache.

Comorbidities among patients with cancer who do and do not develop febrile neutropenia during the first chemotherapy cycle

M. Fisher, W. Langeberg, P. K. Morrow, 2016, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.

Incidence, treatment, and consequences of chemotherapy-induced febrile neutropenia in the inpatient and outpatient settings

G. Lyman, J. Legg, D. Weycker, 2014, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.

Hospitalizations, outcomes, and management costs of febrile neutropenia in patients from a managed care population

F. Vogl, Wansu Chen, C. Chao, 2017, Supportive Care in Cancer.

Determining the Understandability and Acceptability of an Oral Mucositis Daily Questionnaire

L. Sung, D. Tomlinson, P. Judd, 2008, Journal of pediatric oncology nursing : official journal of the Association of Pediatric Oncology Nurses.

Trends in neutropenia-related inpatient events.

M. Dickson, C. Kozma, J. Legg, 2012, Journal of oncology practice.

Patterns of treatment among a cohort of older low-income adults starting new medications for osteoporosis

A. Bower, H. Mogun, D. Solomon, 2014, Osteoporosis International.

Use of Chemotherapy and Same-Day Pegfilgrastim Prophylaxis in US Clinical Practice

D. Weycker, M. Hagiwara, R. Barron, 2014 .

Estimating the cost of an emergency room visit for migraine headache

C. Burk, S. Duff, R. Barron, 2003 .

Risk of mortality in patients with cancer experiencing febrile neutropenia.

K. Tomic, S. Michels, M. Reynolds, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Incidence, treatment, and consequences of chemotherapy-induced febrile neutropenia in the inpatient and outpatient settings

G. Lyman, J. Legg, D. Weycker, 2014, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.

Cost-effectiveness of prophylaxis treatment strategies for febrile neutropenia in patients with recurrent ovarian cancer.

M. Weinstein, G. Lyman, M. Maschio, 2014, Gynecologic oncology.

Discrete choice experiment to estimate breast cancer patients' preferences and willingness to pay for prophylactic granulocyte colony-stimulating factors.

A. Naeim, D. Marshall, J. Legg, 2014, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

Cancer chemotherapy treatment patterns and febrile neutropenia in the US Veterans Health Administration.

O. Baser, D. Dale, W. Langeberg, 2014, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

A retrospective study of the clinical and economic burden during hospitalizations among cancer patients with febrile neutropenia

K. Rothman, F. Ernst, J. Legg, 2013, Journal of medical economics.

Cost of care comparison between cerebral palsy patients treated with botulinum toxin type A and propensity score-matched controls

M. Dickson, C. Kozma, R. Barron, 2005 .